Skip to main content
logo
Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
9.10
-0.05 (-0.55%)
Jul 29, 2026, 12:22 PM EDT - Market open

Xilio Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
53.4843.776.34---
Revenue Growth
476.71%589.88%----
Gross Profit
53.4843.776.34---
Operating Income
-42.24-41.98-60.58-79.13-89.15-75.04
Net Income
-31.3-35.04-58.24-76.4-88.22-75.8
Earnings Per Share
-3.55-4.19-15.24-38.92-45.08-189.28
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
150.33137.5355.2944.7120.39198.05
Total Debt
6.646.958.1412.519.9420.62
Net Cash (Debt)
143.7130.5847.1532.2100.45177.44
Net Cash Growth
76.94%176.94%46.42%-67.94%-43.39%-
Net Cash Per Share
12.4015.6212.3416.4051.34443.09

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-56.31-4.99-18.38-68.62-75.72-80.75
Capital Expenditures
-1.05-0.52-0.04-0.49-1.87-1.1
Free Cash Flow
-57.37-5.51-18.41-69.11-77.59-81.85
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%---
Operating Margin
-78.98%-95.92%-954.95%---
Pretax Margin
-58.52%-80.05%-918.05%---
Profit Margin
-58.52%-80.05%-918.05%---
FCF Margin
-107.26%-12.59%-290.26%---

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
1.020.936.89---